ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2053 entries already.
Barcelona-based epigentics specialist Oryzon Genomics, SA, a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today the successful completion has completed an oversubscribed €30m capital increase through issuing 12,765,958 new shares, priced at €2.35 per share.
Cytovation ASA has baged US$6m to advance Phase II development of its bi-specific pore-forming peptide candidate CY-101 in patients with adrenocortical carcinoma.
RWK Bidco AB, newly founded by the private equity firm KKR (Kohlberg Kravis Roberts & Co.), has identified Swedish separation specialist Biotage AB as a takeover target and submitted an official takeover offer.
Boehringer Ingelheim and synthetic lethality specialist Tessellate Bio have entered into an €500m biobucks global license agreement on oral first-in-class cancer treatments.
Despite the World Trade Organisation’s (WTO) ban of tariffs on pharmaceuticals, US President Donald Trump has announced he would consider imposing tariffs on pharmaceutical products. In a fast reaction, Swiss pharmaceutical giants Roche and Novartis, which are heavily dependent on the US market, have announced upcoming investments in the US as a production location by 2030.
Amsterdam-based uniQure NV’s gene therapy candidate AMT-130 has been granted FDA Breakthrough Therapy Designation for the treatment of the neurodegenerative Huntington’s disease.
Swiss MoonLake Immunotherapeutics AG has secured up to US$500m in non-dilutive financing from life sciences debt specialist Hercules Capital to finance the potential 2027 launch of sonelokimab in hidradenitis suppurativa and clinical trials of the IL-17 dimerisation blocker in palmoplantar pustulosis and other inflammatory indications.
Europe’s decision on how to combine economic growth and decarbonisation in the future depends on the renewal of the EU bioeconomy strategy. The question is whether the EU will fall further behind globally or whether bioeconomy will become the EU’s growth engine.
The EMA has asked the industry to share their thoughts on its draft guidelines for developing and assessing biosimilars. The idea is to make it easier for patients in the EU to get access to biosimilars, while also keeping Europe a good choice for developers.
The Society for Laboratory Automation and Screening (SLAS) has selected 12 start-ups to exhibit at Europe’s premier automation conference as part of its Innovation AveNew programme at SLAS Europe 2025, which takes place from 20-22 May in Hamburg, Germany.